More biotech mergers may be coming.

In a new report, Citi analyst Yigal Nochomovitz takes a look at buyout opportunities in the biotech space. According to Nochomovitz, there are several names that are likely targets in Citi’s coverage universe.

“Average cash for large Pharma/Biotech is near historical highs (~$10B/company, >$180B aggregate),” Nochomovitz explains. “Plus commentary from Pharma/Biotech mgmt. teams over the past ~6 months points to a clear willingness to engage in deal-making.”

Small-midcap biotech stock enterprise values are down about 35 percent so far in 2016. Nochomovitz sees the combination of low valuations for target companies and high cash levels for potential buyers as the groundwork for a coming M&A boom.

Nochomovitz believes that the wild swings in valuations may take time for buyers to adjust to, and the majority of deals may not happen for another one to three quarters. He notes…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!